Compare LGIH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | JANX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.3M | 790.3M |
| IPO Year | 2013 | 2021 |
| Metric | LGIH | JANX |
|---|---|---|
| Price | $38.85 | $14.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $75.90 | $53.60 |
| AVG Volume (30 Days) | 597.2K | ★ 933.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $1,705,504,000.00 | $10,000,000.00 |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $14.33 | N/A |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $12.12 |
| 52 Week High | $69.42 | $35.34 |
| Indicator | LGIH | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 62.58 |
| Support Level | $33.55 | $13.12 |
| Resistance Level | $41.50 | $15.49 |
| Average True Range (ATR) | 2.22 | 0.54 |
| MACD | 0.51 | 0.13 |
| Stochastic Oscillator | 58.27 | 82.48 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.